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ABSTRACT 
Background 
The aim of this study was to investigate the role of the upstream kinase TAK1 and the canonical 
NF-κB pathway colorectal in cancer (CRC). Immunohistochemistry was used to assess the 
expression of TAK1/pTAK1 and canonical NF-κB pathway members in a tissue microarray of 
242 patients. The relationship between expression, the tumour microenvironment and cancer-
specific survival were examined. 
Results 
All the investigated members of the pathway were expressed in CRC tissue.  In addition, 
cytoplasmic pTAK1 was associated with the tumour microenvironment (P=0.045) and cancer-
specific survival (CSS) (P=0.032). When cytoplasmic pTAK1 was stratified by BRAF status, 
cytoplasmic pTAK1 expression association with CSS was strengthened (P=0.014). 
Cytoplasmic IKKβ was significantly associated with the inflammatory cell infiltrate (P=0.015) 
as graded by Klintrup Makinen grade, systemic inflammation as assessed by neutrophil-
lymphocyte ratio (P=0.03) and CSS (P=0.046). On multivariate analysis cytoplasmic IKKβ 
was independently associated with CSS (HR 1.75,95%CI 1.05-2.91, P=0.033).  
Conclusion 
Cytoplasmic pTAK1 was significantly associated with CSS and this was enhanced in patients 
with tumours that expressed wild type BRAF.  High expression of cytoplasmic IKKβ was 
significantly associated with decreased CSS and with markers of the tumour 
microenvironment.  These results support the hypothesis that NF-κB pathway members are 
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poor prognostic markers in patients with CRC, but this requires to be validated in a large 
independent cohort. 
Key Words Colorectal cancer, immunohistochemistry, tumour microenvironment, 
inflammation 
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1.Introduction 
Colorectal cancer remains the second most common cause of cancer death in Europe. Over the 
past few decades outcome has improved, but survival still remains poor with a 5-year survival 
of around 60% (cancerresearchuk, 2017). Currently TNM-based staging is used in colorectal 
cancer, however this is not optimal. Identification of factors relating to both the tumour and the 
microenvironment may help predict prognosis and be used to improve current tools such as 
TNM. Such factors may also provide an insight into potential novel therapies. 
The work of Hanahan and Weinberg (Hanahan & Weinberg, 2011) described the importance 
of tumour associated inflammation in progression of cancers. Recent studies in colorectal 
cancer have identified a role for the local inflammatory cell infiltrate in determining patient 
outcome (Roxburgh & McMillan, 2012). On review of the  literature the presence of a local 
inflammatory infiltrate was consistently associated with an increase in survival and a decrease 
in disease recurrence (Roxburgh & McMillan, 2012) (Mei et al., 2014). Evidence therefore 
suggests that loss of this inflammatory cell infiltrate may play a role in tumour progression and 
metastasis (Park et al., 2014a, Park et al., 2014b). 
While a local inflammatory response has been observed to associate with better cancer-specific 
survival, an elevated systemic inflammatory response has been associated with poorer cancer-
specific survival and an increased risk of recurrence in a number of cancers including colorectal 
cancer (McMillan, 2013).  Markers of the inflammatory response, such as acute phase proteins 
and some components of the white cell population, are measured routinely. These biomarkers 
can be used in conjunction with TNM-based staging as prognostic indicators (Watt, 
2015),(Park et al., 2016). One potential mechanism linking tumour cell signalling with the local 
and systemic inflammatory responses is activation of the Nuclear Factor kappa B (NF-κB) 
pathway. The NF-κB family of transcription factors functions via two main pathways – the 
canonical and the non-canonical pathways (Perkins & Gilmore, 2006). In the canonical 
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pathway the IKK complex, which is composed of the catalytic subunits IKKα and IKKβ and 
the regulatory scaffold protein NEMO, is maintained in the cytoplasm. On stimulation of the 
pathway by cytokines such as TNFα or IL-1, the complex is activated and phosphorylates IκB 
which leads to the release of p50/RelA which then translocates to the nucleus (Perkins & 
Gilmore, 2006). This translocation enables transcription of a variety of genes important in 
inflammatory responses and cell survival and proliferation. 
In vitro studies have suggested that transforming growth factor-β-activated kinase 1 (TAK1), 
an upstream kinase in the pathway, may have a role to play in activation of the pathway. TAK1 
has been demonstrated to be an activating kinase for the IKK complex of the canonical NF-κB 
pathway (Sakurai et al., 1998, Sakurai et al., 1999). Interestingly TAK1 has also been 
associated with a possible third NF-κB pathway which is independent of the controls 
recognised in the other two pathways (Margalef et al., 2012, Margalef et al., 2015). 
The aim of this study was to investigate the role of components of the canonical NF-κB 
pathway and the upstream kinase TAK1 in relation to the tumour microenvironment and 
survival in patients with colorectal cancer. Our hypothesis is that activation of this pathway 
and expression of these proteins have an important role in the determination of the tumour 
phenotype and subsequent outcome. 
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2.Methods 
2.1Patients 
In the current study, 242 patients were selected from a cohort of 274 who had undergone 
elective, potentially curative resection for stage I-III colorectal cancer between 1997 and 2007 
in a single surgical unit – Glasgow Royal Infirmary. A tissue microarray (TMA) had previously 
been constructed. The selection criteria excluded patients who had emergency resection, 
neoadjuvant therapy or who had died within 30 days of surgery. For this cohort no information 
was available with regard to treatment post resection.  Local ethical approval was obtained 
from the West of Scotland Research Ethics Committee and tissue for this analysis was obtained 
from the National Health Service Greater Glasgow and Clyde Tissue Biorepository. 
Markers of systemic inflammation were determined in various ways. Serum C-reactive protein 
(CRP), albumin and differential white cell count were measured within 30 days prior to surgery 
and recorded prospectively. Patients with CRP ≤10mg/L were given a score of 0, patients with 
CRP >10mg/L and albumin ≥35g/L a score of 1 and patients with CRP > 10mg/ml and albumin 
<35g/L a score of 2. The modified Glasgow Prognostic Score (mGPS) (Park et al., 2015), the 
neutrophil:lymphocyte ratio (NLR) (Guthrie et al., 2013)  and the neutrophil:platelet score 
(NPS)  (Watt et al., 2015)  were used to determine the pre-operative inflammatory state. A 
NLR >5 was considered elevated; patients with a platelet count <400x109/L and a neutrophil 
count <7.5 x 109/L were given a score of 0, either a neutrophil count >7.5 x 109/L or a platelet 
count >400x 109/L a score of 1 and those with both an elevated neutrophil and platelet count a 
score of 2. 
2.2 Assessment of the tumour microenvironment 
The tumour stroma percentage (TSP) and the generalised local inflammatory cell infiltrate have 
been previously characterised for this cohort of patients  (Richards et al., 2012, Richards et al., 
2014) (Park, Richards, et al., 2014). If the TSP was ≤50% it was graded low and > 50% graded 
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high. Klintrup- Mӓkinen (KM) grading was used as a measure of the local inflammatory cell 
infiltrate. Low grade was deemed if there was no increase or a mild/patchy increase in 
inflammatory cells at the invasive margin. High grade was assigned if there was a prominent 
band-like inflammatory reaction or florid cup-like inflammatory reaction at the invasive margin 
with destruction of cancer cell islands (Richards et al., 2014).  In addition to KM, the 
immunoscore was used as a measure of local inflammatory cell infiltrate and was calculated 
from CD3 and CD8 counts.  
2.3 Assessment of the expression of members of the canonical NF-κB pathway 
Immunohistochemistry was performed to assess protein levels of TAK1, TAK1 
phosphorylated at threonine 187(pTAK1), IKKβ, p65 (RelA) and phosphorylated p65, using a 
colorectal cancer TMA of 242 patients (Figure 1). Prior to this, antibody specificity was 
confirmed using western blotting to identify a single band of the predicted molecular weight 
(Supplementary Figures 1, 2 & 3). TMA sections (2.5µm) were dewaxed by immersion in 
histoclear then rehydrated using a series of alcohols. Heat induced antigen retrieval was 
performed in a solution of either citrate buffer pH6 or Tris-EDTA pH9 after which the sections 
were incubated in 3% hydrogen peroxide. Non-specific binding was blocked by incubation in 
5% normal horse serum before being incubated with the optimum concentration of primary 
antibody at either room temperature for 2h or overnight at 4oC. Antibody dilutions were 
prepared in antibody diluent (Agilent, London, UK). The primary antibodies and 
concentrations used are as follows; TAK1 (Abcam ab111096) at 1:100, pTAK1 (Immunoway 
YP0424) at 1:200, IKKβ (Abcam ab32135) at 1:500, IKKα (Genway, GWB-662250) at 
1:1000, p65 (Santa Cruz sc-8008) at 1:10 and p-p65 (Abcam ab28856) at 1:50. Staining was 
visualized using EnVisionTM (Dako, Agilent) and 3,3’-diaminobenzidine (DAB, Vector Labs). 
Tissue was counterstained using Harris Haematoxylin before being dehydrated and mounted 
using DPX. 
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The stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden 
City, Hertfordshire, UK at x 20 magnification. Visualization was carried out using Slidepath 
Digital Image Hub, version 4.0.1 (Slidepath, Leica Biosystems, Milton Keynes, UK) at x 400 
magnification. The weighted histoscore method was employed to assess protein expression by 
observer 1 [LB,MK orJQ], with each protein also being scored by a second independent 
observer  [JE] who scored 10% of all tumours to ensure scoring consistency across the study.  
Inter class correlation coefficients of greater than 0.8 were deemed acceptable and Bland 
Altman plots carried out to ensure no scoring bias.  All observers were blinded to the clinical 
and pathological characteristics.   Histoscores were calculated using the following formula: 0x 
% negative staining + 1x % of weakly positive staining + 2x % of moderately positive staining 
+3x % of strongly positive staining giving a range of 0 (minimum) to 300 (maximum). The 
results were considered discordant if the histoscores differed by more than 50. Cytoplasmic 
and nuclear expression, if observed, was calculated separately. 
2.4 Statistical Analysis 
For the purposes of statistical analysis, the weighed histoscore for each protein was divided 
into tertiles to allow us to classify protein expression into low, moderate or high (low, 
moderate, high)(TAK, low<75,moderate 76-115, high>116 )(pTAK1, low <63, moderate 64-
106, high >107)(cytoplasmic IKK  low <33, moderate 34-80, high >81) (p65 low<47, 
moderate48-84, high>85 )  (p-p65,low<150, moderate 151-215,high>216). The relationship 
between clinicopathological characteristics, markers of inflammation and the tumour 
microenvironment and members of the canonical NF-κB pathway was examined using the Chi-
square test for linear trend. The relationship between cytoplasmic pTAK1, cytoplasmic IKKβ 
and cytoplasmic pTAK1/IKKβ stratified with BRAF mutation and cancer-specific survival was 
examined using Kaplan-Meier log-rank analysis. The relationship between expression of 
members of the canonical NF-κB pathway, characteristics of the tumour, microenvironment 
and systemic inflammatory responses and cancer-specific survival was examined using Cox 
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proportional hazards regression; variables with P<0.05 on univariate analysis were entered into 
a multivariate model using a backwards conditional model to calculate hazard ratios (HR) and 
95% confidence intervals (CI). A P value < 0.05 was considered statistically significant. SPSS 
version 22.0 (IBM SPSS) was used for all analysis. 
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3.Results 
 
The characteristics of the 242 patients within the cohort are shown in Table 1. Briefly, 59.5% 
were 65 or older and 52.5% were male. 7% had pathological confirmation of stage I disease, 
49.6% had stage II disease, and 43.4% had stage III disease. 36.4% had right-sided colon 
cancer, 29.3% had left-sided colon cancer, and 34.3% had rectal cancer.  Mismatch repair 
(MMR) deficiency was identified in 14.5% and 21.5% had BRAF mutations. The median 
follow up was 99 months (range 37.5-130 months) with 79 cancer deaths and 66 non-cancer 
deaths.  
TAK1 was not significantly associated with cancer-specific survival (P=0.757), although 
patients that had moderate expression exhibited a reduced mean survival to 118 months (98.5-
137.5 months). 
Univariate analysis demonstrated that expression of cytoplasmic pTAK1 was significantly 
associated with cancer-specific survival (P=0.032) (Table 2). Moderate expression of 
cytoplasmic pTAK1 was associated with decreased cancer-specific survival when compared to 
low and high expression (P=0.032) (Figure 2a). Mean cancer specific survival for patients 
expressing low levels of cytoplasmic pTAK1 was 140 months (122.6-158.1 months) versus 
150 months (133.5-166.0 months) for patients with high expression. 
Moderate expression of cytoplasmic pTAK1 was associated with decreased cancer-specific 
survival when compared to low and high expression (P=0.032) (Figure 2a). When 5 year 
survival data was considered, 48% of patients with moderate pTAK1 expression survived as 
compared to 59% and 65% for those with low and high expression.  
Cytoplasmic pTAK1 and its relationship with clinicopathological characteristics and MMR 
status was examined in the 221 patients (Table 3).  A direct linear association was observed 
between cytoplasmic pTAK and age (P=0.030) and an inverse linear association was observed 
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between cytoplasmic pTAK and Glasgow Microenvironment Score (P=0.045) but not with any 
other characteristics (Table 3).  
Association between cytoplasmic pTAK1 expression and cancer-specific survival was then 
investigated in different subgroups of colorectal cancer patients. Cytoplasmic pTAK1 
expression was not significantly associated with cancer-specific survival in any tumour 
location subgroups (Right sided colon cancer P=0.237, Left sided colon cancer P=0.511, 
Rectum P=0.338) or in MMR competent or MMR deficient patients (Competent P=0.189, 
Deficient P=0.460). Interestingly, when stratified by BRAF status, pTAK1 expression was 
significantly associated with cancer specific survival in patients with wild type BRAF 
(P=0.014) (Figure 3a). When the expression profiles were further analysed, pTAK1 expression 
showed a significant association between high and moderate expression (P=0.004), but not 
between high and low expression (P=0.147) or moderate and low expression (P=0.163). Mean 
cancer specific survival for all patients with wildtype BRAF was 137 months (123.5-149.5 
months). Moderate expression of cytoplasmic pTAK1 reduced this to 113 months (90.9-136.9 
months) as compared to 136 months (113.2-159.7) for low expression and 159 months (141.1-
177.4) for patients with high expression. When only stage 2 disease was considered the 
significant association between CSS and pTAK1 was still observed (n=109, P=0.033). 
However, when stage 3 disease was considered there was no significant association between 
CSS and pTAK1 (n=97, P=0.2423).  
In patients with BRAF mutations present within the tumour, no overall significant association 
with cancer-specific survival and expression of pTAK1 was observed (P=0.105) (Figure 3b). 
However, when analysis was performed to compare those patients with high and low 
expression a significant difference in cancer-specific survival was observed. Those with low 
pTAK1 expression had a mean cancer-specific survival of 163 months (136.7-190), compared 
to 85 months (59.5-110.5) for those with high expression. However, as only 49 patients were 
available for analysis, this should be investigated in a larger cohort.  
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On univariate analysis expression of IKKβ statistically significantly associated with cancer-
specific survival (P=0.046) and was independently associated with cancer-specific survival on 
multivariate analysis (HR 1.75,95%CI 1.05-2.91, P=0.033) (Table 2).  
Cytoplasmic IKKβ was associated with cancer-specific survival, high expression was 
associated with poor outcome when compared to low and moderate expression (P=0.046) 
(Figure 2b). Mean cancer-specific survival for patients expressing low levels of IKKβ was 158 
months (142.3-173.2 months) and for those expressing moderate levels was 142 months (123.8-
159.9 months); this was reduced to 125 months (105.5-145.0 months) for patients with high 
cytoplasmic IKKβ expression. When 5 year survival data was considered, 51% of patients 
expressing high levels of cytoplasmic IKKβ, were alive at 5 years, compared to 59% of patients 
with moderate expression and 71% of patients whose tumours expressed low levels of IKKβ.  
When this was assessed across tumour state 2 and stage 3 the result was negated in stage 2 
disease (P=0.446, 99 patients) but enhanced in stage 3 disease (P=0.161, 97 patients) although 
not reaching significance due to being underpowered.  
Cytoplasmic IKKβ and its relationship with clinicopathological characteristics and MMR 
status was examined in 211 of the 242 patients (Table 4). MMR status was not available for 31 
of the patients due to insufficient tissue.  A likelihood relationship was observed between 
cytoplasmic IKKβ and Klintrup-Makinen grade (P=0.015) and a direct linear relationship was 
observed between IKKβ Glasgow Microenvironment Score (P=0.029) and an indirect 
relationship was observed between IKKβ and Neutrophil-Lymphocyte ratio (P=0.03). There 
was no significant relationship observed between any of the other characteristics. 
Association between cytoplasmic IKKβ expression and cancer-specific survival was then 
investigated in different subgroups of colorectal cancer patients. Cytoplasmic IKKβ expression 
was not significantly associated with cancer-specific survival at any tumour location (Right 
sided colon cancer P=0.075, Left sided colon cancer P=0.687, Rectal cancer P=0.463), in either 
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MMR groups (Competent P=0.134, Deficient P=0.112) or in BRAF wild type or mutated 
tumours (Wild type P=0.067, Mutated P=0.264).  
The relationship between clinicopathological factors, the tumour microenvironment, systemic 
inflammatory responses, pTAK1, IKKβ and cancer-specific survival was then examined in 
multivariate analysis (Table 5). Of the factors investigated, those that independently associated 
with cancer-specific survival were the Glasgow microenvironment score (HR 2.67, 95%CI 
1.41-5.03, P=0.002) and cytoplasmic IKKβ (HR 1.75,95%CI 1.05-2.91, P=0.033) (Table 2). 
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4.Discussion 
In a cohort of 242 patients, cytoplasmic pTAK1 was significantly associated with cancer 
specific survival and this was enhanced when stratified by BRAF status but did not reach 
significance possibly due to the small number of patients and/or events in the mutated BRAF 
subgroup.  In addition, high expression of cytoplasmic IKKβ was significantly associated with 
decreased survival and with markers of the tumour microenvironment. The present study 
demonstrates that members of the canonical NF-κB pathway are expressed in tumours of 
patients with colorectal cancer. Cytoplasmic pTAK1 was associated with cancer-specific 
survival, which was enhanced by stratification with BRAF, but not with microsatellite 
instability (MSI) status (indicated by MMR protein status).  Cytoplasmic IKKβ was associated 
with decreased cancer-specific survival and with the tumour microenvironment but not with 
BRAF or MSI status. On multivariate analysis only cytoplasmic IKKβ was independently 
associated with survival.   
Surprisingly patients with moderate pTAK1 expression had the poorest survival, with patients 
who have high or low expression of pTAK having a better prognosis.  We hypothesis that this 
might be due to the fact the TAK is normally present and activate in epithelial cells and it is 
only when the normal expression levels differ i.e. increase or decrease that the normal 
homeostasis and signalling of the cell is disrupted.  An increase or decrease may represent 
dysregulation of the pathway from the normal state leading to a worse prognosis. In patients 
with wild type BRAF, moderate expression of cytoplasmic pTAK1 was associated with poor 
outcome. More detailed analysis revealed a significant association between moderate and high 
expression but not between low and moderate or low and high.  In contrast, in mutated BRAF, 
high expression of cytoplasmic pTAK1 was observed to be related to poor outcome, moderate 
expression with moderate outcome and low expression with a better outcome.  However, 
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although a trend was observed, this did not reach significance possibly due to low patient 
numbers and events available for analysis in this subgroup. Further analysis of the expression 
profiles revealed a significant association between low and high expression, but not between 
moderate expression and low or high expression. This suggests that pTAK1 expression 
warrants further investigation in a larger cohort. 
TAK1 is a serine/threonine protein kinase of the MAPK kinase family. It is an upstream 
regulating kinase in the NF-κB pathway and has been recognised as having a role in the 
activation of the canonical NF-κB pathway(Sakurai et al.,1998,Sakurai et al.,1999). It has been 
reported to activate the IκB kinase (IKK) complex which is composed of IKKα, IKKβ and 
NEMO (Sakurai et al., 1999). It forms a complex with its activator proteins  TAK1-binding 
protein 1 and 2 (TAB1 and TAB2) (Takaesu et al., 2012)  and it has been demonstrated that 
the kinase activity of TAK1 is regulated by modifications to TAK1 and the TABs. 
Phosphorylation can occur on several serine and threonine residues in the activation loop of 
TAK1 (Singhirunnusorn et al., 2005, Yu et al., 2008). Phosphorylation at Thr-187 has been 
associated with activation of TAK1 on stimulation by TNFα(Singhirunnusorn et al., 2005), and 
this is the main autophosphorylation site. 
A study investigating TAK1 in gastric cancer reported that elevated expression of TAK1 was 
associated with a decreased patient survival and that in cell lines TAK1 selective inhibitors 
resulted in increased apoptosis (Yang et al., 2017).   However, in contrast to the present study 
only the presence or absence of TAK1 expression was investigated.  Multiple studies have 
investigated TAK1 expression in relation to KRAS status (Singh et al., 2012, McNew et al., 
2016); however there is little information on TAK1 expression in relation to BRAF status.   A 
limitation of the study is that KRAS status was not available and it would be interesting to 
investigate further in patients whose KRAS status was known. 
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In  the present study activated TAK1, was assessed by TAK1 phosphorylated at  Thr-187 which 
is recognised  as being associated with activation of TAK1 (Singhirunnusorn et al., 2005).   
Moderate expression of phosphorylated TAK1 at Thr-187, as a measure of activated TAK1, 
was associated with poor cancer-specific survival. Stratification by BRAF status demonstrated 
that those patients with mutant BRAF had decreased cancer-specific survival if cytoplasmic 
pTAK1 expression was high.  KRAS mutations are common in colorectal cancers, and studies 
employing colorectal cancer cell lines and mouse models have reported that TAK1 is important 
regulator of tumour cell viability(Singh et al., 2012).  Work carried out in pancreatic  cell lines  
suggests that silencing or inhibition of TAK1 may have a therapeutic effect in relation to 
chemoresistance (Melisi et al., 2011).  However, numbers in our cohort were low and therefore 
TAK1 expression and activation warrants further investigation in a larger patient cohort.  
 A role for IKKβ in colitis-associated cancer has previously been reported (Greten et al., 2004). 
Using mouse models, deletion of IKKβ in intestinal epithelial cells leads to a decrease in 
tumour size but not a reduction in inflammation (Greten et al., 2004). A role for IKKβ in the 
initiation of colitis-associated tumours has also been reported (Koliaraki et al., 2015). Vlantis 
(Vlantis et al., 2011) demonstrated that constitutive activation of IKKβ in mouse intestinal 
epithelial cells induces tumours.  This supports our observation that elevated cytoplasmic IKKβ 
expression is associated with a reduced cancer-specific survival.  
In conclusion the current study investigated the role of components of the canonical NF-κB 
pathway and the upstream kinase TAK1 in relation to the tumour microenvironment and 
survival in patients with colorectal cancer.  The data from this study suggest that the abundance 
of pTAK1 and IKKβ in the cytoplasm of CRC cells may have some prognostic value, however 
this requires validation in a larger independent cohort. 
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Figure Legends  
Figure 1 Representative images of  IKKβ weak (a), moderate(b) and strong (c), TAK1 weak 
(d), moderate (e) and strong (f), p-TAK1 weak (g), moderate (h) and strong (i), p65 weak (j), 
moderate (k) and strong(l) and p-p65 weak (m), moderate (o) and strong(p) expression using 
IHC (x100 magnification).  Image at x400 demonstrating cytoplasmic and nuclear expression 
patterns (q).  
Figure 2 The relationship between cytoplasmic pTAK1 and cytoplasmic IKKβ expression and 
cancer-specific survival of patients undergoing elective, potentially curative resection of stage 
I-III colorectal cancer: (a) cytoplasmic pTAK1 expression (P=0.032) and (b) cytoplasmic IKKβ 
expression (P=0.046). 
Figure 3 The relationship between cytoplasmic pTAK1 stratified with BRAF expression and 
cancer-specific survival of patients undergoing elective, potentially curative resection of stage 
I-III colorectal cancer: (a) cytoplasmic pTAK1 stratified with wildtype BRAF expression 
(P=0.014) and (b) cytoplasmic pTAK1 stratified with mutated BRAF expression (P=0.105). 
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Supplementary Figure Legends 
Figure 1. Antibody specificity determined for  TAK1 and p-TAK1 using cell lysates prepared 
from cells stimulated with TNFα (20ng/ml) over a time course of 120 minutes. Tubulin was 
used as a loading control. 
Figure 2. Antibody specificity determined for IKKβ using lysates prepared from cells 
transfected with si RNA. Tubulin used as loading control. 
Figure 3. Antibody specificity determined for  p65 and  p-p65 using lysates prepared from cell 
stimulated with TNFα (20ng/ml) and IL-1 (20ng/ml) over a time course of 120 minutes. 
Tubulin was used as a loading control. 
Table 1. Patient characteristics  
  Patient Cohort 
n=242 (%) 
Age 
<65 
>65  
 
98(40.5) 
144(59.5) 
Tumour Location 
Right-sided colon 
Left-sided colon 
Rectal  
 
88(36.4) 
71(29.3) 
83(34.3) 
TNM-stage 
I 
II 
III  
 
17(7.0) 
120(49.6) 
105(43.4) 
T-stage 
1 
2 
3 
4  
 
8(3.3) 
18(7.4) 
150(62.0) 
66(27.3) 
N-stage 
0 
1 
2 
 
137(56.6) 
80(33.1) 
25(10.3) 
  
Differentiation 
Moderate/well 
Poor  
 
213(88.0) 
29(12.0) 
Venous Invasion 
Absent 
Present  
 
157(64.9) 
85(35.1) 
MMR Status 
Competent 
Deficient 
Unknown 
 
BRAF 
Wildtype 
Mutated 
Unknown  
 
193(79.8) 
35(14.5) 
14(5.8) 
 
 
165(68.2) 
52(21.5) 
25(10.3) 
Survival 
Alive 
Cancer Death 
        All causes of Death 
 
97(40.1) 
 79(32.6) 
145(59.9) 
 
  
Table 2: Univariate and Multivariate analysis of members of the Canonical NF-κB pathway and 
cancer-specific survival in patients with colorectal cancer (n=242) 
 
Biomarker Univariate 
HR (95% CI) 
P Value  Multivariate 
HR (95% CI) 
P Value 
All Patients (n=242)      
Cytoplasmic TAK 1.04(0.78-1.39) 0.757    
Cytoplasmic pTAK 0.90(0.67-1.18) 0.032    
Nuclear pTAK 0.94(0.71-1.26) 0.500    
Cytoplasmic IKKβ 1.47(1.08-2.01) 0.046  1.75(1.05-2.91) 0.033 
Nuclear IKKβ 1.03(0.76-1.40) 0.648    
Cytoplasmic IKKα 0.96(0.58-1.60) 0.877    
Nuclear IKKα  0.71(0.42-1.19) 0.193    
Cytoplasmic p65 1.10(0.82-1.47) 0.800    
Cytoplasmic pp65 0.94(0.68-1.29) 0.917    
Nuclear pp65 0.81(0.59-1.10) 0.169    
  
 Table 3: Relationship between cytoplasmic phosphorylated TAK1 and clinicopathological 
characteristics in patients with colorectal cancer (n=221) 
  Low (%) Mod (%) High (%)  P-value 
Host and tumour characteristics 
Age         <65 
>65  
36(16.3) 
39(17.6) 
28(12.7) 
46(20.8) 
22(10.0) 
50(22.6) 
 0.030 
Sex         Female                                                     
                Male 
34(15.4) 
41(18.6) 
36(16.3) 
38(17.2) 
30(13.6) 
42(19.0) 
  
0.698 
Tumour Location 
Right colon 
Left colon 
Rectum 
 
25(11.3) 
22(10.0) 
28(12.7) 
 
28(12.7) 
17(7.7) 
27(12.2) 
 
28(12.7) 
29(13.1) 
18(8.1) 
  
0.235 
TNM-stage 
I 
II 
III 
 
7(3.2) 
34(15.4) 
34(15.4) 
 
5(2.3) 
37(16.7) 
38(17.2) 
 
3(1.4) 
38(17.2) 
31(14.0) 
  
0.775 
T-stage 
1 
2 
3 
4 
 
3(1.4) 
7(3.2) 
44(19.9) 
21(9.5) 
 
 
1(0.5) 
6(2.7) 
48(21.7) 
21(9.5) 
 
 
4(1.8) 
2(0.9) 
47(21.3) 
19(8.6) 
  
0.868 
N-stage 
0 
1 
2 
 
41(18.6) 
23(10.4) 
11(5.0) 
 
23(10.4) 
25(11.3) 
25(11.3) 
 
11(5.0) 
7(3.2) 
6(2.7) 
  
0.443 
Differentiation 
Moderate/well 
Poor 
 
65(29.4) 
10(4.5) 
 
62(28.1) 
12(5.4) 
 
66(29.9) 
6(2.7) 
  
0.336 
Mismatch Repair Status* 
MRC 
MRD 
 
61(27.6) 
11(5.0) 
 
61(27.6) 
10(4.5) 
 
55(24.9) 
11(5.0) 
  
0.828 
Tumour Microenvironment 
Klintrup-Makinen grade (KM-grade, 220)  
 
Weak 
Strong 
 
 
45(20.5) 
30(13.6) 
 
 
50(22.7) 
23(10.5) 
 
 
52(23.6) 
20(9.1) 
  
 
0.273 
Tumour-Stroma percentage (TSP, 199) 
Low 
High 
 
55(27.7) 
13(6.5) 
 
46(23.1) 
20(10.1) 
 
47(23.6) 
18(9.1) 
  
0.289 
 
Glasgow Microenvironment Score (GMS, 
203) 
0 
1 
2 
 
 
30(14.8) 
31(15.3) 
7(3.5) 
 
 
23(11.3) 
28(13.8) 
17(8.4) 
 
 
20(9.9) 
33(16.3) 
14(6.9) 
   
 
0.045 
 
 
Immunoscore (198) 
0 
1 
2 
3 
4 
 
23(11.6) 
6(3.0) 
12(6.1) 
11(5.6) 
12(6.1) 
 
29(14.7) 
13(6.6) 
16(8.1) 
4(2.0) 
5(2.5) 
 
26(13.1) 
9(4.6) 
14(7.1) 
10(5.1) 
8(4.0) 
  
 
0.319 
Systemic Inflammatory Response 
     
Serum CRP (221) 
Normal 
High 
 
41(18.6) 
34(15.4) 
 
43(19.5) 
31(14.0) 
 
45(21.4) 
27(12.2) 
  
0.627 
Serum Albumin (221) 
Normal 
Low 
 
63(28.5) 
12(5.4) 
 
62(28.1) 
12(5.4) 
 
62(28.1) 
10(4.5) 
  
0.910 
Modified Glasgow Prognostic Score 
(mGPS, 221) 
0 
1 
2 
 
 
41(18.6) 
25(11.3) 
9(4.1) 
 
 
25(11.3) 
23(10.4) 
20(9.1) 
 
 
9(4.1) 
8(3.6) 
7(3.2) 
  
 
0.371 
 
 
      
      
      
Neutrophil-Lymphocyte Ratio  (NLR, 190) 
 
≤5 
>5 
 
 
48(25.3) 
18(9.5) 
 
 
47(24.7) 
12(6.3) 
 
 
 
 
50(26.3) 
15(7.9) 
  
 
0.571 
Neutrophil-Platelet Score (NPS,117) 
0 
1 
2 
 
24(20.5) 
17(14.5) 
1(0.9) 
 
17(14.5) 
12(10.3) 
10(8.6) 
 
1(0.9) 
3(2.6) 
2(1.7) 
  
0.442 
*Of the available patients only 209 had information for both pTAK1 expression and MMR status 
 
  
Table 4: Relationship between cytoplasmic IKK β and clinicopathological characteristics in patients 
with colorectal cancer (n=211) 
  Low (%) Mod (%) High (%)  P-value 
Host and tumour characteristics 
Age 
<65 
>65 
 
32(15.2) 
41(19.4) 
 
27(12.8) 
45(21.3) 
 
26(12.3) 
40(19.0) 
  
0.728 
Sex 
Female 
Male 
 
37(17.5) 
36(17.1) 
 
32(15.2) 
40(19.0) 
 
32(15.2) 
34(16.1) 
  
0.748 
Tumour Location 
Right colon 
Left colon 
Rectum 
 
30(14.2) 
20(9.5) 
23(10.9) 
 
20(9.5) 
21(10.0) 
20(9.5) 
 
23(10.9) 
25(11.9) 
24(11.4) 
  
0.376 
TNM-stage 
I 
II 
III 
 
6(2.8) 
33(15.6) 
34(16.1) 
 
4(1.9) 
38(18.0) 
30(14.2) 
 
5(2.4) 
28(13.3) 
33(15.6) 
  
0.709 
T-stage 
1 
2 
3 
4 
 
2(1.0) 
6(2.8) 
45(21.3) 
20(9.5) 
 
4(1.9) 
4(1.9) 
48(22.8) 
16(7.6) 
 
2(1.0) 
6(2.8) 
36(17.1) 
22(10.4) 
  
0.728 
N-stage 
0 
1 
2 
 
39(18.5) 
28(13.3) 
6(2.8) 
 
28(13.3) 
21(10.0) 
26(12.3) 
 
6(2.8) 
9(4.3) 
7(3.3) 
  
0.620 
Differentiation 
Moderate/well 
Poor 
 
64(30.3) 
9(4.3) 
 
66(31.3) 
6(2.8) 
 
57(27.0) 
9(4.3) 
  
0.832 
Mismatch Repair Status* 
MRC 
MRD 
 
60(28.4) 
12(5.7) 
 
65(30.8) 
7(3.3) 
 
56(23.5) 
9(4.3) 
  
0.461 
Tumour Microenvironment 
Klintrup-Makinen grade (KM-
grade, 210)  
                Weak 
Strong 
 
 
39(18.6) 
34(16.2) 
 
 
52(24.8) 
19(9.1) 
 
 
48(22.9) 
18(8.6) 
  
 
0.015 
Tumour-Stroma percentage (TSP, 
193) 
Low 
High 
 
51(26.4) 
15(7.8) 
 
49(25.4) 
17(8.8) 
 
44(22.8) 
17(8.8) 
  
0.506 
Glasgow Microenvironment 
Score (GMS, 197) 
0 
1 
2 
 
 
34(17.3) 
26(13.2) 
8(4.1) 
 
 
19(9.6) 
32(16.2) 
17(8.6) 
 
 
18(9.1) 
32(16.2) 
11(5.6) 
  
 
0.029 
Immunoscore (193) 
0 
1 
2 
3 
4 
 
16(8.3) 
12(6.2) 
18(9.3) 
9(4.7) 
10(5.2) 
 
30(15.5) 
10(5.2) 
11(5.7) 
12(6.2) 
6(3.1) 
 
28(14.5) 
8(4.2) 
10(5.2) 
3(1.6) 
10(5.2) 
  
0.069 
Systemic Inflammatory Response 
     
Serum CRP (211) 
Normal 
High 
 
42(19.9) 
31(14.7) 
 
43(20.4) 
29(13.7) 
 
41(19.4) 
25(11.9) 
  
0.583 
 
Serum Albumin (211) 
Normal 
Low 
 
65(30.8) 
8(3.8) 
 
57(27.0) 
15(7.1) 
 
60(28.4) 
6(2.8) 
  
0.798 
Modified Glasgow Prognostic 
Score (mGPS, 211) 
0 
1 
2 
 
 
42(19.9) 
24(11.4) 
7(3.3) 
 
 
43(20.4) 
19(9.0) 
10(4.7) 
 
 
41(19.4) 
21(10.0) 
4(1.9) 
  
 
0.488 
Neutrophil-Lymphocyte Ratio  
(NLR, 186) 
 
≤5 
>5 
 
 
46(24.7) 
20(10.8) 
 
 
49(26.3) 
10(5.4) 
 
 
52(28.0) 
9(4.8) 
  
 
0.030 
 
Neutrophil-Platelet Score (NPS, 
117) 
0 
1 
2 
 
26(22.2) 
16(13.7) 
2(1.7) 
 
16(13.7) 
10(8.6) 
8(6.8) 
 
2(1.7) 
1(0.9) 
2(1.7) 
  
0.169 
*Of the available patients information for both cytoplasmic IKKβ and MMR status was only available in 209 
cases. 
 
  
Table 5: Univariate and Multivariate analysis of members of NF-kB pathway, 
characteristics of the tumour, microenvironment, systemic inflammatory responses and 
cancer specific survival in patients with colorectal cancer (n=242) 
Biomarker Univariate  
HR (95% CI) 
P-value  Multivariate  
HR (95% CI) 
P-value 
All Patients (n=242)      
Sex (female/male) 1.18(0.75-1.84) 0.474    
Tumour location  
(right colon/left colon/rectum) 
1.06(0.81-1.38) 0.843  
 
 
TNM Stage (I/II/III) 2.26(1.50-3.41) <0.001    
N-Stage (0/1/2) 1.82(1.35-2.45) <0.001    
Differentiation (moderate or well/poor) 1.76(0.95-3.25) 0.068    
Mismatch Repair (MRC/MRD) 0.96(0.51-1.83) 0.909    
Klintrup-Makinen Grade  (strong/weak) 2.36(1.34-4.14) 0.002    
GMS (0/1/2) 1.95(1.40-2.71) <0.001  2.67(1.41-5.03) 0.002 
Immunoscore (0/1/2/3/4) 0.60(0.48-0.73) <0.001    
Serum CRP (Normal/High) 1.82(1.17-2.84) 0.007    
Serum Albumin (Normal/Low) 1.94(1.15-3.28) 0.012  0 0.980 
mGPS (0/1/2) 1.68(1.25-2.26) 0.001    
Neutrophil count (≤7.5 x 109L/>7.5 x 109L) 1.84(1.00-3.39) 0.047    
Platelet count (≤400 x 109L/>400 x 109L) 1.909(0.85-4.20) 0.110    
NPS (0/1/2) 1.98(1.19-3.28) 0.022    
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